An interventional study of Levcromakalim and Saline in Headache, Migraine and Aura, sponsored by Danish Headache Center. Completed at 1 site in Denmark. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-05-17.
Sponsored by Danish Headache Center · Not applicable, Interventional, and Other
To investigate the migraine inducing effect of levcromakalim in patients with migraine with aura.
1,558 studies on the registry are indexed under Migraine Disorders; 301 are open to participants now.
This study's enrollment of 35 is below the median of 80 across 1,197 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →Danish Headache Center is the lead sponsor of 129 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Levcromakalim
Drug: Saline
To investigate the role of levcromakalim compared with placebo in migraine with aura patients
To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Headache incidence
Difference in incidence of headache following infusion of levcromakalim compared to placebo in patients with migraine with aura.
Time frame: 10 minutes before until 24 hours after infusion of levcromakalim or placebo
Migraine incidence
Difference in incidence of migraine-like headache following infusion of levcromakalim compared to placebo in patients with migraine with aura.
Time frame: 10 minutes before until 24 hours after infusion of levcromakalim or placebo
Aura incidence
Difference in incidence of migraine aura following infusion of levcromakalim compared to placebo in patients with migraine with aura.
Time frame: 10 minutes before until 24 hours after infusion of levcromakalim or placebo
Headache intensity
The area under the curve (AUC) for headache following infusion of levcromakalim compared to placebo in patients with migraine with aura
Time frame: 10 minutes before until 24 hours after infusion of levcromakalim or placebo
Heart rate
Change in heart rate measured in Beats per minute (BPM) following infusion of levcromakalim compared to placebo in patients with migraine with aura
Time frame: 10 minutes before until 120 minutes after infusion of levcromakalim or placebo
Blood pressure
Change in blood pressure (systolic and diastolic) measured in mmHg following infusion of levcromakalim compared to placebo in patients with migraine with aura
Time frame: 10 minutes before until 120 minutes after infusion of levcromakalim or placebo
Plan to share: Undecided
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cromakalim